Trial Profile
Retinal Ganglion Cell Function After Repeated Intravitreous Ranibizumab in Diabetic Macular Edema
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 28 Aug 2018
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 21 Aug 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 Mar 2014 New trial record